Herbs (Global Traditional) · European
Valerian (Valeriana officinalis) (Valeriana officinalis)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Valerian (Valeriana officinalis) is a European herb containing valerenic acid and other compounds that enhance GABA neurotransmitter activity in the brain. Clinical studies demonstrate its effectiveness for improving sleep quality and reducing mild depression symptoms.
Valerian (Valeriana officinalis) is a perennial herb native to Europe and Asia, primarily sourced from the roots and rhizomes of the plant. It is typically extracted using alcohol or water-based methods to produce tinctures, teas, or dry extracts, with valepotriates, valerenic acids, and volatile oils as key constituents.
A systematic review and meta-analysis of 16 RCTs found valerian may improve subjective sleep quality (relative risk 1.8, 95% CI 1.2-2.9), though heterogeneity and methodologic issues limited firm conclusions. Key trials include a crossover RCT in hemodialysis patients (PMID: 33936782) showing significant improvements in sleep, depression, and anxiety, and studies in postmenopausal women (PMID: 21775910) and young adults with mild insomnia (PMID: 37899385).
Clinically studied doses include 100 mg three times daily for anxiety/insomnia, 320 mg nightly for sleep-onset insomnia, and unspecified oral doses for 1 month in hemodialysis patients. Recent trials have used standardized extracts, though specific standardization details were not provided in available research. Consult a healthcare provider before starting any new supplement.
Valerian root is not consumed as a food for macronutrient value; it is used as a medicinal herb, typically in doses of 300–900 mg dried root or 2–3 g of dried root as tea. **Key bioactive compounds:** • **Valerenic acid** (0.1–0.8% of dried root) – primary sesquiterpene responsible for GABAergic activity via modulation of GABA-A receptor subunit β3; bioavailability is moderate orally with hepatic first-pass metabolism. • **Isovaleric acid** – short-chain fatty acid contributing to characteristic odor and mild sedative effects. • **Iridoids (valepotriates):** isovaltrate, valtrate, and didrovaltrate (0.5–2.0% of dried root) – chemically unstable compounds with sedative and cytotoxic properties; largely decompose during drying and storage, reducing oral bioavailability significantly. • **Sesquiterpenes:** acetoxyvalerenic acid, hydroxyvalerenic acid, valerenal, valeranone (collectively 0.3–0.9% of dried root). • **Flavonoids:** linarin (6-S-apiosyl-8-hydroxyl-luteolin), hesperidin, and methylapigenin – contribute to anxiolytic effects; linarin synergizes with valerenic acid. • **Lignans:** hydroxypinoresinol and pinoresinol (trace amounts). • **GABA content:** approximately 0.04–0.8 mg/g of dried root – though exogenous GABA has limited blood-brain barrier penetration, it may act on enteric nervous system or peripheral GABA receptors. • **Essential oil (0.5–1.5%):** contains bornyl acetate (major component, ~30–50% of oil), camphene, β-pinene, borneol, and eugenyl isovalerate. • **Minerals (per dried root):** calcium (~1.2–2.0 mg/g), magnesium (~0.8–1.5 mg/g), potassium (~8–12 mg/g), manganese, zinc, and iron in trace amounts – though these are not consumed in nutritionally significant quantities at typical medicinal doses. • **Amino acids:** glutamine, arginine, and tyrosine in trace quantities. • **Polysaccharides and tannins** present in minor concentrations. **Bioavailability notes:** Valerenic acid reaches peak plasma levels in approximately 1–2 hours; half-life is estimated at 1.1 hours. Valepotriates are largely degraded in the GI tract and during processing into baldrinal compounds, which retain some but reduced bioactivity. Aqueous extracts (teas) are relatively low in valerenic acid but richer in GABA and water-soluble flavonoids; ethanol-based tinctures and standardized extracts (typically standardized to 0.8% valerenic acid) provide more consistent sesquiterpene delivery. Co-administration with food may slow absorption but does not significantly reduce overall bioavailability.
Valerian's primary compounds valerenic acid, isovaleric acid, and valeranone enhance GABAergic neurotransmission by increasing GABA availability and binding to GABA-A receptors. These compounds also inhibit GABA breakdown by blocking GABA transaminase enzyme activity. Additionally, valerian constituents may interact with adenosine receptors and serotonin pathways, contributing to its sedative and mood-regulating effects.
A randomized controlled trial in hemodialysis patients demonstrated significant sleep quality improvement with valerian, reducing Pittsburgh Sleep Quality Index scores from 7.6 to 3.2 (p<0.001). Meta-analysis data shows a relative risk of 1.8 for subjective sleep improvement compared to placebo. Clinical trials also indicate depression symptom reduction, with Beck Depression Inventory scores decreasing by 6.5 points versus 2.3 in control groups. Most studies used 300-600mg daily dosages over 2-4 week periods.
Valerian is generally well-tolerated, with mild side effects including daytime drowsiness, headache, and gastrointestinal upset in some users. It may potentiate the effects of sedative medications, benzodiazepines, and alcohol, requiring dosage adjustments. Valerian can interact with medications metabolized by cytochrome P450 enzymes, particularly CYP3A4 substrates. Pregnant and breastfeeding women should avoid valerian due to insufficient safety data, and users should discontinue use at least two weeks before scheduled surgery.
